Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease

References

• Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431–440.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430–1438.
   PubMed Web of Science ®Google Scholar
• Liverani E, Scaioli E, Digby RJ, et al. How to predict clinical relapse in inflammatory bowel disease patients. WJG. 2016;22(3):1017–1033.
   PubMed Web of Science ®Google Scholar
• Consigny Y, Modigliani R, Colombel JF, et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis. 2006;12(7):551–557.
   PubMed Web of Science ®Google Scholar
• Bitton A, Dobkin PL, Edwardes MD, et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut. 2008;57(10):1386–1392.
   PubMed Web of Science ®Google Scholar
• Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988;10(4):401–405.
   PubMed Web of Science ®Google Scholar
• Peterson CG, Sangfelt P, Wagner M, et al. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest. 2007;67(8):810–820.
   PubMed Web of Science ®Google Scholar
• Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817–1826 e2.
   PubMed Web of Science ®Google Scholar
• Zhulina Y, Cao Y, Amcoff K, et al. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther. 2016;44(5):495–504.
   PubMed Web of Science ®Google Scholar
• Ertekin V, Selimoğlu MA, Turgut A, et al. Fecal calprotectin concentration in celiac disease. J Clin Gastroenterol. 2010;44(8):544–546.
   PubMed Web of Science ®Google Scholar
• Alibrahim B, Aljasser MI, Salh B. Fecal calprotectin use in inflammatory bowel disease and beyond: a mini-review. Can J Gastroenterol Hepatol. 2015;29(3):157–163.
   PubMed Web of Science ®Google Scholar
• Peterson CG, Eklund E, Taha Y, et al. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterology. 2002;97(7):1755–1762.
   PubMed Web of Science ®Google Scholar
• Peterson CG, Lampinen M, Hansson T, et al. Evaluation of biomarkers for ulcerative colitis comparing two sampling methods: fecal markers reflect colorectal inflammation both macroscopically and on a cellular level. Scand J Clin Lab Invest. 2016;76(5):393–401.
   PubMed Web of Science ®Google Scholar
• Wagner M, Peterson CG, Stolt I, et al. Fecal eosinophil cationic protein as a marker of active disease and treatment outcome in collagenous colitis: a pilot study. Scandinavian J Gastroenterol. 2011;46(7-8):849–854.
   PubMed Web of Science ®Google Scholar
• Venge P, Bystrom J, Carlson M, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999;29(9):1172–1186.
   PubMed Web of Science ®Google Scholar
• Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008;38(5):709–750.
   PubMed Web of Science ®Google Scholar
• Moqbel R, Lacy P. Exocytotic events in eosinophils and mast cells. Clin Exp Allergy. 1999;29(8):1017–1022.
   PubMed Web of Science ®Google Scholar
• Carlson MG, Peterson CG, Venge P. Human eosinophil peroxidase: purification and characterization. J Immunol. 1985;134(3):1875–1879.
   PubMed Web of Science ®Google Scholar
• Travers J, Rothenberg ME. Eosinophils in mucosal immune responses. Mucosal Immunol. 2015;8(3):464–475.
   PubMed Web of Science ®Google Scholar
• Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239–241.
   Web of Science ®Google Scholar
• Lasson A, Stotzer PO, Ohman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9(1):26–32.
   PubMed Web of Science ®Google Scholar
• Wagner M, Peterson CG, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. WJG. 2008;14(36):5584–5589. discussion 8.
   PubMed Web of Science ®Google Scholar
• Saitoh O, Kojima K, Sugi K, et al. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol. 1999;94(12):3513–3520.
   PubMed Web of Science ®Google Scholar
• Lampinen M, Backman M, Winqvist O, et al. Different regulation of eosinophil activity in Crohn's disease compared with ulcerative colitis. J Leukocyte Biol. 2008;84(6):1392–1399.
   PubMed Web of Science ®Google Scholar
• Kampe M, Lampinen M, Stolt I, et al. PI3-kinase regulates eosinophil and neutrophil degranulation in patients with allergic rhinitis and allergic asthma irrespective of allergen challenge model. Inflammation. 2012;35:230–239.
   PubMed Web of Science ®Google Scholar
• Jonsson UB, Bystrom J, Stalenheim G, et al. Polymorphism of the eosinophil cationic protein-gene is related to the expression of allergic symptoms. Clin Exp Allergy. 2002;32(7):1092–1095.
   PubMed Web of Science ®Google Scholar
• Blom K, Rubin J, Halfvarson J, et al. Eosinophil associated genes in the inflammatory bowel disease 4 region: correlation to inflammatory bowel disease revealed. WJG. 2012;18:17–18.
   Web of Science ®Google Scholar
• Trulson A, Bystrom J, Engstrom A, et al. The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications. Clin Exp Allergy. 2007;37(2):208–218.
   PubMed Web of Science ®Google Scholar
• Rubin J, Venge P. Asparagine-linked glycans determine the cytotoxic capacity of eosinophil cationic protein (ECP). Mol Immunol. 2013;55(3-4):372–380.
   PubMed Web of Science ®Google Scholar
• Carvalho AT, Elia CC, de Souza HS, et al. Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J Clin Gastroenterol. 2003;36(2):120–125.
   PubMed Web of Science ®Google Scholar
• Carlson M, Raab Y, Peterson C, et al. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol. 1999;94(7):1876–1883.
   PubMed Web of Science ®Google Scholar
• Zagai U, Skold CM, Trulson A, et al. The effect of eosinophils on collagen gel contraction and implications for tissue remodelling. Clin Exp Immunol. 2004;135(3):427–433.
   PubMed Web of Science ®Google Scholar